scholarly journals Bionic women and men: Heart failure and an artificial heart pump

2019 ◽  
pp. 72-77
Author(s):  
Eric J. Stöhr ◽  
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Heart Pump

Measurements of Rotordynamic Forces on an Artificial Heart Pump Impeller

2007 ◽  
Vol 129 (11) ◽  
pp. 1422-1427 ◽  
Author(s):  
Takayuki Suzuki ◽  
Romain Prunières ◽  
Hironori Horiguchi ◽  
Tomonori Tsukiya ◽  
Yoshiyuki Taenaka ◽  
...  
Keyword(s):  
Artificial Heart ◽  
Journal Bearing ◽  
Centrifugal Pumps ◽  
Pump Impeller ◽  
Fluid Forces ◽  
Heart Pump ◽  
Wide Range ◽  
Artificial Hearts ◽  
Rotordynamic Forces ◽  
Magnetic Drive

In centrifugal pumps for artificial hearts, a magnetic drive with lightly loaded journal bearing system is often used. In such a system, the rigidity of the bearing is small and the impeller usually rotates over the critical speed. In such cases, the rotordynamic fluid forces play an important role for shaft vibration. In the present study, the characteristics of the rotordynamic fluid forces on the impeller were examined. The rotordynamic fluid forces were measured in the cases with/without the whirling motion. It was found that the rotordynamic forces become destabilizing in a wide range of positive whirl. The effect of leakage flow was also examined.

Construction of an Artificial Heart Pump Performance Test System

2006 ◽  
Vol 6 (4) ◽  
pp. 151-158 ◽  
Author(s):  
Yingjie Liu ◽  
Paul Allaire ◽  
Yi Wu ◽  
Houston Wood ◽  
Don Olsen
Keyword(s):  
Artificial Heart ◽  
Performance Test ◽  
Test System ◽  
Pump Performance ◽  
Heart Pump

Current state of total artificial heart therapy and introduction of the most important total artificial heart systems

2019 ◽  
Vol 64 (3) ◽  
pp. 247-250
Author(s):  
Sotirios Spiliopoulos ◽  
Vera Hergesell ◽  
Andrae Wasler ◽  
Otto Dapunt
Keyword(s):  
Heart Failure ◽  
Organ Donation ◽  
Clinical Outcomes ◽  
Artificial Heart ◽  
Cardiac Transplantation ◽  
Total Artificial Heart ◽  
Successful Implementation ◽  
Technical Requirements ◽  
Current State ◽  
End Stage

AbstractDue to the declining instances of organ donation, total artificial heart (TAH) therapy is of increasing importance for the management of end-stage biventricular heart failure. We introduce the currently most important established and novel TAH systems (SynCardia, CARMAT, ReinHeart, BiVACOR), report clinical outcomes and discuss technical requirements for the successful implementation of TAH therapy as an alternative to cardiac transplantation.

HEART PUMP AND OXYGENATOR

PEDIATRICS ◽  
1957 ◽  
Vol 19 (6) ◽  
pp. 1124-1128
Author(s):  
W. T. Mustard
Keyword(s):  
World War Ii ◽  
Artificial Heart ◽  
Heart Surgery ◽  
Human Subjects ◽  
Open Heart Surgery ◽  
World War ◽  
Heart Pump ◽  
The World ◽  
Cardiac Bypass ◽  
Selection Of

THIS PAPER is a general review of the development of the artificial heart-lung to facilitate open-heart surgery. At the close of World War II many centers began investigating the possibility of total cardiac bypass. Oven the past decade, pump oxygenerators of various types have become popular and recent clinical successes throughout the world have given further impetus to the study of problems posed by the artificial heart-lung apparatus. The subject divides itself into three separate parts, the first two being concerned with the maintenance of life in an experimental animal during a total cardiac bypass. One must take all the blood from the animal and return it to the animal by means of a pump. Secondly, one must oxygenate the blood before returning it. The third part of the problem confronting the surgeon is the selection of cases and correction of defects in human subjects. The pumping mechanism must duplicate as nearly as possible the action of the chambers of the heart. Pumping action must be smooth so as to prevent hemolysis and to avoid turbulence with thrombosis. It is not difficult to construct a pump with which hemolysis can be kept to relatively negligible amounts. Most of the pumps in use throughout the world give an hemolysis of less than 50 mg of hemoglobin per 100 ml of blood, which is perfectly safe. Turbulence with thrombosis can be overcome by removing valves inside the stream and placing valves outside of, rather than within the stream of blood. Furthermore, heparinization of the blood lessens the tendency to thrombosis.

Defibrillator-Heart Pump: An Implantable Ventricular Assist Device With Integrated Defibrillator Component—The First In Vitro Testing

2019 ◽  
Vol 26 (6) ◽  
pp. 720-724
Author(s):  
Anas Aboud ◽  
Kai Liebing ◽  
Charlie Abraham ◽  
Jan-Christian Reil ◽  
Yara Turkistani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Therapeutic Option ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
In Vitro Testing ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Heart Pump ◽  
Increased Risk

Left ventricular assist devices (LVADs) are an important therapeutic option for patients with end-stage heart failure waiting for heart transplantation or in older patients as definite therapy for heart failure. Interestingly, about 62% of patients receiving LVADs do not have an automatic implantable cardioverter-defibrillator (AICD) at the time of implantation, although these patients have increased risk of being confronted with dangerous arrhythmia. Therefore, an LVAD system including AICD function is a reasonable alternative for such heart failure patients thereby avoiding a second surgical intervention for AICD implantation. In this article, a newly developed system including LVAD and AICD function is introduced, and we also report its first in vitro testing.

The Biocompatibility Challenges in the Total Artificial Heart Evolution

2019 ◽  
Vol 21 (1) ◽  
pp. 85-110 ◽  
Author(s):  
Eleonora Dal Sasso ◽  
Andrea Bagno ◽  
Silvia T.G. Scuri ◽  
Gino Gerosa ◽  
Laura Iop
Keyword(s):  
Heart Failure ◽  
Artificial Heart ◽  
Comprehensive Analysis ◽  
Therapeutic Options ◽  
Total Artificial Heart ◽  
Final Treatment ◽  
End Stage Heart Failure ◽  
End Stage

There are limited therapeutic options for final treatment of end-stage heart failure. Among them, implantation of a total artificial heart (TAH) is an acceptable strategy when suitable donors are not available. TAH development began in the 1930s, followed by a dramatic evolution of the actuation mechanisms operating the mechanical pumps. Nevertheless, the performance of TAHs has not yet been optimized, mainly because of the low biocompatibility of the blood-contacting surfaces. Low hemocompatibility, calcification, and sensitivity to infections seriously affect the success of TAHs. These unsolved issues have led to the withdrawal of many prototypes during preclinical phases of testing. This review offers a comprehensive analysis of the pathophysiological events that may occur in the materials that compose TAHs developed to date. In addition, this review illustrates bioengineering strategies to prevent these events and describes the most significant steps toward the achievement of a fully biocompatible TAH.

Sign in / Sign up

Export Citation Format

Share Document